1. Home
  2. MFA vs LBRX Comparison

MFA vs LBRX Comparison

Compare MFA & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$9.42

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$27.89

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
LBRX
Founded
1997
2015
Country
United States
United States
Employees
N/A
27
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
850.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MFA
LBRX
Price
$9.42
$27.89
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$11.05
$46.60
AVG Volume (30 Days)
1.4M
140.2K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
14.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.02
N/A
P/E Ratio
$7.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.78
$13.40
52 Week High
$10.57
$33.47

Technical Indicators

Market Signals
Indicator
MFA
LBRX
Relative Strength Index (RSI) 39.44 40.86
Support Level $9.38 $22.39
Resistance Level $10.26 $33.47
Average True Range (ATR) 0.22 1.68
MACD -0.08 -0.60
Stochastic Oscillator 9.55 11.96

Price Performance

Historical Comparison
MFA
LBRX

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: